Introduction
Bladder cancer is a common disease affecting more than 12,500 patients in the UK and an estimated 63,000 in the US each year with 5,000 and 13,000 deaths respectively [1, 2] . Worldwide it is estimated that >300,000 new cases occur each year, with the highest incidence in industrialised countries and areas where infection with the parasite Schistosoma haematobium is endemic. In the latter case, many of the tumours that develop are squamous cell carcinomas. In contrast, the majority of non-schistosomiasisrelated cases are transitional cell carcinoma and only this group of tumours will be discussed here. In the western world, bladder cancer is a disease of middle and old age. Smoking is a significant risk factor as are certain occupational carcinogens [3] . There is a male:female ratio of ~3:1 and in men in the UK bladder cancer is now the fourth most common malignancy.
amplifications of 11q and loss of 10q but none of these are frequent (Table 3) . Amplifications of 11q include the cyclin D1 gene (CCND1) which is involved in regulation of cell cycle progression from G1 to S phase via the Rb pathway ( Figure 2 ).
As bladder cancer is a disease of the middle to late decades of life, it is predicted that multiple heritable changes are required for tumour development. Thus it is surprising that so few genetic changes have been identified in low-grade pTa tumours, which represent the major group at diagnosis. Epigenetic events represent an alternative type of heritable change and promoter hypermethylation of APC, p14 ARF and RASSF1A has been described in the urine of almost all bladder cancer patients including those with low grade/stage tumours [13] . However, as for many other heritable changes, hypermethylation of several of these promoter regions shows significant association with tumour grade and/or stage [14, 15] . Indeed, one mechanism by which methylation can be increased is by upregulation of expression of DNA methyltransferase I, which occurs in cells with loss of Rb or p53 function [16, 17] , events found predominantly in invasive UCC.
Low-grade pTa tumours are genetically stable. Synchronous or metachronous tumours from the same patient generally show a striking identity in the genetic alterations found [18, 19] . LOH of chromosome 9 is the least divergent event, indicating that this is likely to be an early change, whilst other events occur during independent evolution of different tumour sub-clones [19] . As relatively few common events have been identified in this group of tumours, efforts are in progress using expression and genomic microarray technology to identify other genetic or epigenetic events that may contribute to their development.
Chromosome 9
Chromosome 9 LOH is found in more than 50% of all bladder tumours regardless of grade and stage [10, 20, 21] . Many UCCs have LOH of the entire chromosome, suggesting loss of function of tumour suppressor genes on both chromosome arms. Thus, identification of these genes is considered vital to aid understanding of disease pathogenesis and to provide useful clinical markers and targets. Critical regions of LOH have been mapped on both 9p and 9q. In small primary tumours, the frequency of small deletions Currently, one region of loss is mapped on 9p (9p21) and at least three regions on 9q (at 9q22, 9q32-q33 and 9q34) [22, [25] [26] [27] [28] . Candidate genes within these regions are CDKN2A/ARF (p16/p14ARF) and CDKN2B (p15) at 9p21 [29] [30] [31] [32] [33] , PTCH (Gorlin Syndrome gene) at 9q22 [25, 34] , DBC1 at 9q32-q33 [26, 35, 36] and TSC1 (Tuberous Sclerosis Syndrome gene 1) at 9q34 [37] [38] [39] .
The CDKN2A/ARF locus on 9p21 encodes 2 proteins, p16 and p14 ARF both of which are key cell cycle regulators. These genes share coding region in exons 2 and 3 but have distinct exons 1. The protein products are translated in different reading frames to generate two entirely different proteins, p16, which is negative regulator of the Rb pathway and p14 Three genes on 9q are implicated; PTCH, the Gorlin syndrome gene, is within a small region of deletion at 9q22. was present in 82% of low-grade tumours, indicating that a common biological mechanism may be shared by virtually all superficial UCCs. Mutations of FGFR3 and TP53 are also somewhat mutually exclusive [56, 57] but in this case, mutation of TP53 is associated predominantly with tumours of high grade and stage, so it is hypothesised that these events are not equivalent, but rather are associated with and define the two distinct tumour groups. In addition to frequent chromosome 9 deletion, many genetic alterations have been reported in muscle invasive UCC (Tables 1-3 ). These include alterations to known genes and genomic alterations for which the target genes are currently unknown. Karyotype studies have identified losses of 1p, 6q, 9p, 9q and 13q
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and gains of 5p in more than 15% of cases. CGH and LOH analyses have confirmed and extended these findings (Tables 2 and 3) .
Oncogenes
As However, it still remains unclear whether it represents a useful prognostic marker and a recent metaanalysis of more than 3000 tumours has only indicated a small association between p53 positivity by immunohistochemistry and poor prognosis [87] . Reduced expression of p21 which acts downstream of p53, is associated with disease progression [88, 89] . The Rb pathway regulates progression from G1 to S phase of the cell cycle (Figure 2 ). The RB1 gene has not been screened for small mutations in UCC but As indicated above, the locus encoding p16 and p14 ARF is commonly deleted in UCC of all grades and stages. These proteins interact with and link the Rb and p53 pathways ( Figure 2 ) and due to the multiple regulatory feedback mechanisms that operate in these pathways [94] , inactivation of both of these together is likely to provide further freedom from the G1 checkpoint than conferred by either p53 or Rb inactivation alone. It is predicted that tumours with p53 and Rb or p16 loss will be more aggressive than those with either p53 or Rb loss alone. Rb and p53 have been assessed together in several clinical studies and this prediction is borne out. Altered p21 expression both alone and in combination with other events also represents a significant risk factor [88, 89] . To date an assessment of all genes known to be involved in the G1 checkpoint has not been carried out on a single patient series but such an analysis may achieve even greater predictive power.
The cyclin D1 gene CCND1 is amplified in some bladder tumours, both superficial and invasive.
However, the frequency of amplification is insufficient to explain all cases with over-expression. It is likely that over-expression in many cases is the indirect result of other alterations e.g. activation of the MAPK or PI3-kinase pathways (Figure 3 ). To date there is no clear consensus on the clinical significance of over-expression. Interestingly, cyclin D1 is a possible target of the Wnt/β-catenin pathway and recently some high-grade bladder tumours with mutations in β-catenin were reported [95] . This represents an alternative mechanism for cyclin D1 activation in these tumours and is accompanied by myc overexpression and a more aggressive phenotype than the over-expression associated with gene amplification, found in low grade tumours with papillary architecture [96] .
PTEN
PTEN (phosphatase and tensin homologue deleted on chromosome ten) maps to 10q23, a region of common LOH in UCC of high grade and stage [97] [98] [99] . PTEN has both lipid and protein phosphatase activity, a key substrate being the signalling lipid PtIns(3,4,5)P 3 a major product of PI3-kinase which is activated by various tyrosine kinase receptors. Thus PTEN is a negative regulator of this signalling pathway, which affects cell phenotype in various ways including effects on proliferation, apoptosis and Loss of PTEN leads to PI3-kinase pathway activation with high levels of phosphorylated AKT.
As discussed above, the TSC1 product hamartin also acts in the PI3-kinase pathway ( This group of invasive tumours displays genetic instability with rapid and major genetic divergence in related tumours from the same patient and this is commonly chromosomal instability (CIN) rather than microsatellite instability (MIN) [111] . The genetic differences between minimally invasive (pT1) and more deeply invasive tumours (>pT2) are not significant, suggesting that tumours with the ability to break through the basement membrane are aggressive lesions. Although T1 tumours often have good clinical outcome, this may reflect complete resection rather than lack of tumour aggression. Certain genetic changes including gains of 3p22-25 and 5p and losses of 4p11-15, 5q15-23, 6q22-23 and 10q24-26, appear to be associated with tumour progression in this group [112] . In one CGH study, muscle invasive tumour samples and paired metastatic samples were compared but no significant metastasis-associated markers were identified [113] .
Carcinoma in situ
CIS is a difficult lesion to obtain as a fresh tissue sample due to its fragility. By definition, CIS has normal urothelial thickness and commonly the cells, which are highly anaplastic, are only weakly adherent and tend to dissociate during cystoscopy ( Figure 1c ). Thus most specimens are only recognised retrospectively in paraffin-embedded samples and only a few studies have attempted to assess genetic changes in such lesions. An initial study by Spruck et al [114] suggested that dysplasias and CIS had a high frequency of TP53 mutation but a relatively low frequency of chromosome 9 loss. A subsequent study [115] found chromosome 9 loss and a range of alterations similar to those reported in muscle invasive UCC. These apparently discrepant results may be explained by a more recent study [116] which indicates significant differences in CIS that is found in isolation (primary CIS) and CIS that occurs in association with a papillary tumour. Chromosome 9 loss was infrequent in primary CIS and common in CIS associated with synchronous carcinoma. If confirmed, this may indicate 2 distinct forms of CIS with different developmental pathways. CIS found in association with high grade superficial UCC and containing chromosome 9 deletion could represent a precursor for the associated papillary tumour. Recently, attempts have been made to apply bioinformatic modelling to define possible genetic pathways of UCC development [120, 121] . Some associations of events have been identified. For example, Hoglund et al, using principle component analysis of data obtained via conventional cytogenetic analysis of 200 UCCs identified two potential cytogenetic pathways, one initiated by -9, followed by -11p and 1q+ and a second initiated by +7 followed by 8p-and +8q. The latter group appeared to contain more aggressive tumours (T1-T3) whereas the former contained Ta-T2 tumours [120] . More recently, Bulashevska et al [121] used a Bayesian network model to analyse LOH data for 17 chromosomes in 123
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papillary UCCs (all grades). Such an analysis will not detect increased copy number and hence it is difficult to directly compare the findings with those of Hoglund et al [120] . However, the network obtained showed 9p and 9q as the most probable primary event with 8p-and 17-as major subsequent events that lead to progression. Other events showed relationship to one or either of these e.g losses of 1q, 18q and 10q were related to 8p loss and 5p/q loss to 17p loss. A more recent analysis [122] based on cytogenetic data confirms several of these associations and predicts two pathways that show distinct lesions but ultimately converge, one initiated by +7 and the other by -9.
Based on molecular and histopathological observations, a model for the molecular pathogenesis of UCC has developed ( Figure 5 ). Almost certainly this is too simple but it does provide a useful anchor for molecular studies. Mutation of FGFR3 defines the large group of superficial tumours. FGFR3 and TP53 There are several gaps in our current understanding. First there may be more alterations in lowgrade papillary superficial UCC that remain to be discovered. Another outstanding question is what the significance of pT1 tumours is. Are these merely muscle invasive tumours caught in their journey towards the muscle or do they represent a distinct group? Genetic findings tend to support the former conclusion but this is not proven. No significant differences have yet been found between muscle invasive UCC and the metastases that develop from them. Possibly this reflects the early migration of cells to distant sites without the requirement for additional changes or possibly there are determinants of progression and metastasis yet to be identified. Finally, the critical question concerning possible differences in primary and UCC-associated dysplasia/CIS [116] which may confirm the existence of a third pathway to urothelial neoplasia requires careful examination of more samples.
Information from global expression and genomic profiling
Global profiling via expression and genomic microarray technologies may provide answers to some of these outstanding questions. Detailed discussion of findings is beyond the scope of this commentary but some findings are worthy of comment.
Expression arrays have been used to classify bladder tumours and provide gene expression patterns that define the major histopathological subtypes [123] [124] [125] [126] [127] . Encouragingly a classification set of transcripts recently identified by Blaveri et al [126] , when tested on data from a previous study [128] showed successful classification into superficial and muscle invasive tumour groups.
Several reports have attempted to go beyond simple classification to identify subsets of tumours within grade/stage classes and to predict outcome. For example, a study of Ta tumours generated a "molecular classifier" that provided predictive information on risk of recurrence [128] . Two studies have reported comparisons of groups of superficial tumours that did or did not progress [129, 130] . In the first this may have clinical application in excluding such patients from intensive cystoscopic follow-up. In the second study [129] , expression profiles discriminated between Ta, Tis, T1 and T2 tumours and showed that in general T1 tumours were more similar to T2 than to Ta tumours. A predictor of progression was built that correctly classified 33/42 samples (sensitivity 85.7%; specificity 71.4%).
A study of superficial tumours with or without associated CIS, a known high-risk predictor,
showed that these could be accurately classified by expression profile and a 16 gene CIS classifier was derived that performed well. Interestingly "normal" mucosa from cystectomy specimens with adjacent CIS was found to contain the CIS signature, indicating that in bladders with CIS, there is widespread urothelial alteration [131] . prognosis with 78% success using a 24-gene signature.
Although firm conclusions cannot yet be drawn about critical markers for classification and prediction of prognosis, it is re-assuring that common genes have emerged from several expression studies as potential markers for particular subgroups of tumours. These include cathepsin E (CTSE) which is more highly expressed in normal urothelium and superficial tumours [126, 129] and FABP4, high expression of which was present in normal urothelium and associated with superficial tumours that progressed but was reduced in muscle invasive tumours [129] and in CIS [131] . 
Conclusions
The past few years have seen an exponential accumulation of molecular information on UCC.
Encouragingly, expression array analyses, which have provided orders of magnitude more information than has ever been acquired on gene expression in this disease, have largely confirmed that groupings based on tumour grade and stage are biologically valid. These studies and some of the more simple genetic analyses have also indicated that some subgroups such as papillary tumours that progress or have associated CIS do indeed form distinct groups at the molecular level. Doubt remains about the precise genetic relationships of putative precursor lesions, low-and high-grade papillary and muscle invasive UCCs. However, it comes as no surprise that there are now several lines of evidence for more complexity in pathogenesis than can be explained by a simple two-pathway model. Possibly both "Jeckyll and Hyde"
and "chalk and cheese" are represented here. The challenge will be to recognise these scenarios and to predict clinical phenotype in every patient. Undoubtedly, the application of array-based genomic approaches used in combination with expression profiling and high throughput mutation scanning will yield a wealth of information in the future that may answer some of the outstanding questions about the 
